Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
US10994028B2 · kind B2 · utility
0Cited by
2References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 8, 2017 |
| Grant date | May 4, 2021 |
| Priority date | — |
| Expiry date | Sep 9, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/15051
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.